Pfizer recalls sickle cell anaemia drug due to risk of complications and death
US drugmaker Pfizer said on Wednesday it was recalling Oxbryta, a treatment for sickle-cell anaemia, from all markets where it is approved, citing risks of painful complications and fatalities. Pfizer acquired Oxbryta, also known as voxelotor, as part of its $5.4 billion buyout of Global Blood Therapeutics in 2022.
ENTRADAS POPULARES
Putin may discuss Ukraine peace deal with Trump
noviembre 22, 2024
Spain’s vice-president Ribera blames floods on climate change
noviembre 22, 2024
Storm lashes northwestern US, killing two people
noviembre 22, 2024
Iceland volcano erupts for tenth time in three years
noviembre 22, 2024
TRANSMISIÓN EN VIVO